Prevalence of protective antibody levels against hepatitis B infection among healthcare workers in a tertiary care hospital in India

Authors

  • Ramesh Thanikachalam Associate Professor, Department of General Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India https://orcid.org/0000-0001-6728-1191
  • Sathyan Elangovan Assistant Professor, Department of General Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India https://orcid.org/0000-0001-7434-0313
  • Jercy Grace Assistant Professor, Department of General Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India https://orcid.org/0000-0003-1005-5112

DOI:

https://doi.org/10.3126/ajms.v14i3.51794

Keywords:

Hepatitis B; Hepatitis B vaccines; Healthcare workers

Abstract

Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV carriers
(HCC).

Aims and Objectives: This study aims to assess the anti-HBs antibody titer level against various levels of healthcare workers (HCWs) and to assess the need for booster dose hepatitis B vaccination.

Materials and Methods: This study was conducted at Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India, from July 2022 to December 2022. A total of 218 HCWs were divided into two groups: Group A (vaccinated ≥5 years ago) and Group B (vaccinated in past 5 years). The serum from 2 mL blood was separated and tested for anti HBs antibody titer by electrochemiluminescense immunoassay method.

Results: The mean and standard deviation values of Anti-HBsAg titer between Group A and Group B was not statistically significant (P=0.08467).

Conclusion: Our study demonstrates that people who have had vaccinations are unsure of whether they are responders or non-responders, and to determine this, they must have had their titer evaluated only 1–2 months after receiving their third dosage of hepatitis B vaccine. As a result, they still run the risk of contracting hepatitis B and strongly need a booster dose of the hepatitis B vaccine.

Downloads

Download data is not yet available.
Abstract
73
PDF
155

Downloads

Published

2023-03-01

How to Cite

Thanikachalam, R. ., Elangovan, S., & Grace, J. (2023). Prevalence of protective antibody levels against hepatitis B infection among healthcare workers in a tertiary care hospital in India. Asian Journal of Medical Sciences, 14(3), 118–121. https://doi.org/10.3126/ajms.v14i3.51794

Issue

Vol. 14 No. 3 (2023)

Section

Original Articles

License

Copyright (c) 2023 Asian Journal of Medical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).